| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698903 | Clinical Oncology | 2013 | 7 Pages |
Abstract
The improved biochemical control of disease seen in these patients with EBRTÂ +Â HDR brachytherapy coupled with equitoxic early and late urinary and bowel morbidity, indicate a therapeutic advantage, which has now been confirmed by the results for general and prostate-related quality of life changes, despite a decline in erectile function.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
P.J. Hoskin, A.M. Rojas, P.J. Ostler, R. Hughes, G.J. Lowe, L. Bryant,